View ValuationFamiCord 将来の成長Future 基準チェック /36FamiCord利益と収益がそれぞれ年間108.9%と3.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に17.1% 110.6%なると予測されています。主要情報108.9%収益成長率110.61%EPS成長率Healthcare 収益成長12.8%収益成長率3.1%将来の株主資本利益率17.11%アナリストカバレッジLow最終更新日01 Jun 2026今後の成長に関する最新情報お知らせ • May 30FamiCord AG Confirms Earnings Guidance for 2026FamiCord AG confirmed earnings guidance for 2026. The Management Board confirms its guidance for the 2026 financial year, expecting revenues in a range of EUR 80 million to EUR 90 million.Price Target Changed • May 21Price target decreased by 13% to €6.50Down from €7.50, the current price target is provided by 1 analyst. New target price is 71% above last closing price of €3.81. Stock is up 0.3% over the past year. The company is forecast to post earnings per share of €0.03 next year compared to a net loss per share of €0.26 last year.お知らせ • Nov 22FamiCord AG Confirms Earnings Guidance for the Financial Year 2025FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million.Price Target Changed • Jun 04Price target increased by 15% to €6.00Up from €5.21, the current price target is provided by 1 analyst. New target price is 27% above last closing price of €4.74. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year.Breakeven Date Change • May 02No longer forecast to breakevenThe analyst covering VITA 34 no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.05m in 2024. New forecast suggests the company will make a loss of €1.50m in 2025.Price Target Changed • Nov 16Price target decreased to €10.50Down from €12.50, the current price target is an average from 2 analysts. New target price is 19% above last closing price of €8.86. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.59 next year compared to a net loss per share of €0.63 last year.すべての更新を表示Recent updatesReported Earnings • Jun 01First quarter 2026 earnings released: €0.01 loss per share (vs €0.04 loss in 1Q 2025)First quarter 2026 results: €0.01 loss per share (improved from €0.04 loss in 1Q 2025). Revenue: €21.5m (down 2.7% from 1Q 2025). Net loss: €208.0k (loss narrowed 69% from 1Q 2025). Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • May 30FamiCord AG Confirms Earnings Guidance for 2026FamiCord AG confirmed earnings guidance for 2026. The Management Board confirms its guidance for the 2026 financial year, expecting revenues in a range of EUR 80 million to EUR 90 million.Price Target Changed • May 21Price target decreased by 13% to €6.50Down from €7.50, the current price target is provided by 1 analyst. New target price is 71% above last closing price of €3.81. Stock is up 0.3% over the past year. The company is forecast to post earnings per share of €0.03 next year compared to a net loss per share of €0.26 last year.お知らせ • May 14FamiCord AG, Annual General Meeting, Jun 24, 2026FamiCord AG, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.お知らせ • Dec 24+ 3 more updatesFamiCord AG to Report Q3, 2026 Results on Nov 23, 2026FamiCord AG announced that they will report Q3, 2026 results on Nov 23, 2026お知らせ • Nov 22FamiCord AG Confirms Earnings Guidance for the Financial Year 2025FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million.お知らせ • May 16FamiCord AG, Annual General Meeting, Jun 25, 2025FamiCord AG, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jan 09+ 3 more updatesVITA 34 AG to Report Q1, 2025 Results on May 28, 2025VITA 34 AG announced that they will report Q1, 2025 results on May 28, 2025Reported Earnings • Aug 31Second quarter 2024 earnings released: €0.10 loss per share (vs €0.07 loss in 2Q 2023)Second quarter 2024 results: €0.10 loss per share (further deteriorated from €0.07 loss in 2Q 2023). Revenue: €19.5m (up 6.0% from 2Q 2023). Net loss: €1.41m (loss widened 19% from 2Q 2023). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Reported Earnings • Jun 05First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023)First quarter 2024 results: €0.05 loss per share (improved from €0.18 loss in 1Q 2023). Revenue: €18.6m (up 3.6% from 1Q 2023). Net loss: €785.0k (loss narrowed 73% from 1Q 2023). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings.New Risk • Jun 05New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€129k net loss in 2 years). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$93.3m).Price Target Changed • Jun 04Price target increased by 15% to €6.00Up from €5.21, the current price target is provided by 1 analyst. New target price is 27% above last closing price of €4.74. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year.Breakeven Date Change • May 02No longer forecast to breakevenThe analyst covering VITA 34 no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.05m in 2024. New forecast suggests the company will make a loss of €1.50m in 2025.お知らせ • Apr 27+ 3 more updatesVITA 34 AG to Report Q1, 2024 Results on May 31, 2024VITA 34 AG announced that they will report Q1, 2024 results on May 31, 2024New Risk • Apr 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€82.6m market cap, or US$89.5m).New Risk • Apr 04New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €25m Forecast net loss in 2 years: €1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding).New Risk • Feb 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€86.3m market cap, or US$93.1m).Reported Earnings • Nov 26Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022)Third quarter 2023 results: €0.10 loss per share (further deteriorated from €0.02 loss in 3Q 2022). Revenue: €20.4m (up 9.4% from 3Q 2022). Net loss: €1.62m (loss widened €1.41m from 3Q 2022). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.Reported Earnings • Sep 01Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022)Second quarter 2023 results: €0.07 loss per share (improved from €0.30 loss in 2Q 2022). Revenue: €18.4m (up 10% from 2Q 2022). Net loss: €1.19m (loss narrowed 74% from 2Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.New Risk • Jun 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (€87.1m market cap, or US$95.0m).New Risk • Jun 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.6m (US$89.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Jun 02First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022)First quarter 2023 results: €0.18 loss per share (in line with 1Q 2022). Revenue: €17.9m (up 16% from 1Q 2022). Net loss: €2.89m (loss widened 2.8% from 1Q 2022). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.お知らせ • May 12Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug CandidateVita 34 AG has started enrollment in Phase I of the Tarcidomgen Kimleucel clinical trial. The drug candidate is an anti-CD19 CAR-T, a chimeric antigen receptor, and the first candidate in Vita 34's Cell & Gene Therapy (CGT) portfolio. After recent clearance by the responsible authorities and the responsible ethics committee, the start of the clinical trial under the name CARLA and the recruitment of the first patient ("First Patient In") is imminent. A total of up to ten patients are expected to be recruited for Phase I of the study, which is the usual number for this type of drug. The recruitment will take place via two clinical centers in Poland. The Management Board of Vita 34 AG expects Phase I to be completed by the end of 2023. The costs related with this phase of the trial have already taken into consideration in the guidance published for 2023. The principal investigator of the CARLA study is Prof. Grzegorz Basak, Professor and Chairman of the Department of Hematology, Transplantation and Internal Medicine at the University Hospital of Warsaw Medical University. Tarcidomgen Kimlucel is being developed through FamiCordTx, a subsidiary of Vita 34 AG that aims to develop proprietary CAR-T drug therapies. FamiCordTx has secured an exclusive license from a U.S. supplier for this purpose in the past and has optimized the technology according to European GMP standards. CAR-T therapy uses a patient's own T cells, which are genetically engineered in a laboratory to produce a protein called a chimeric antigen receptor (CAR). When the modified T-cells are returned to the patient, the CAR enables the T- cells to seek out and destroy cancer cells wherever they are in the body. According to a report by Allied Market Research, the global CAR-T cell therapy market was valued USD 1,7 billion in 2021 and is expected to reach USD 6.1 billion by 2031.Reported Earnings • May 01Full year 2022 earnings released: €1.71 loss per share (vs €0.63 loss in FY 2021)Full year 2022 results: €1.71 loss per share (further deteriorated from €0.63 loss in FY 2021). Revenue: €68.9m (up 143% from FY 2021). Net loss: €27.1m (loss widened €23.4m from FY 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance.お知らせ • Dec 03+ 3 more updatesVITA 34 AG to Report Q3, 2023 Results on Nov 21, 2023VITA 34 AG announced that they will report Q3, 2023 results on Nov 21, 2023Reported Earnings • Nov 24Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021)Third quarter 2022 results: €0.02 loss per share (down from €0.11 profit in 3Q 2021). Revenue: €18.7m (up 230% from 3Q 2021). Net loss: €209.0k (down 147% from profit in 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance.Price Target Changed • Nov 16Price target decreased to €10.50Down from €12.50, the current price target is an average from 2 analysts. New target price is 19% above last closing price of €8.86. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.59 next year compared to a net loss per share of €0.63 last year.Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021)Second quarter 2022 results: EPS: €0.30. Revenue: €16.6m (up 206% from 2Q 2021). Net loss: €4.61m (loss widened €4.60m from 2Q 2021). Over the next year, revenue is forecast to grow 48%, compared to a 3.7% growth forecast for the Healthcare industry in Germany.Reported Earnings • Jun 02First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: €0.18 loss per share (down from €0.01 loss in 1Q 2021). Revenue: €15.5m (up 188% from 1Q 2021). Net loss: €2.81m (loss widened €2.77m from 1Q 2021). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 103%, compared to a 4.8% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.Reported Earnings • May 02Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: €0.63 loss per share (down from €0.37 profit in FY 2020). Revenue: €28.4m (up 42% from FY 2020). Net loss: €3.67m (down 343% from profit in FY 2020). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 17% compared to a 5.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Price Target Changed • Apr 27Price target increased to €25.00Up from €19.10, the current price target is provided by 1 analyst. New target price is 108% above last closing price of €12.00. Stock is down 28% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.Price Target Changed • Dec 18Price target increased to €21.10Up from €19.10, the current price target is an average from 2 analysts. New target price is 40% above last closing price of €15.10. Stock is up 23% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: €5.82m (up 7.4% from 3Q 2020). Net income: €575.0k (down 23% from 3Q 2020). Profit margin: 9.9% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • Sep 01Second quarter 2021 earnings releasedThe company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €5.44m (up 11% from 2Q 2020). Net loss: €12.0k (down 102% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has remained flat.Reported Earnings • Jun 01First quarter 2021 earnings releasedThe company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €5.38m (up 15% from 1Q 2020). Net loss: €38.0k (down 110% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 02Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019)The company reported a solid full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: €20.1m (flat on FY 2019). Net income: €1.51m (up 104% from FY 2019). Profit margin: 7.5% (up from 3.7% in FY 2019). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Feb 12New 90-day high: €14.05The company is up 12% from its price of €12.55 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.90 per share.Is New 90 Day High Low • Jan 23New 90-day high: €13.00The company is up 5.0% from its price of €12.35 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Healthcare industry, which is also up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.80 per share.Price Target Changed • Nov 25Price target raised to €17.50Up from €15.00, the current price target is an average from 2 analysts. The new target price is 41% above the current share price of €12.45. As of last close, the stock is down 8.8% over the past year.Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS €0.18The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €5.42m (up 1.4% from 3Q 2019). Net income: €745.0k (up 357% from 3Q 2019). Profit margin: 14% (up from 3.0% in 3Q 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Analyst Estimate Surprise Post Earnings • Nov 14Revenue and earnings miss expectationsRevenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 2.9%. Over the next year, revenue is forecast to grow 7.4%, compared to a 4.3% growth forecast for the Healthcare industry in Germany.Is New 90 Day High Low • Oct 29New 90-day low: €11.15The company is down 5.0% from its price of €11.70 on 30 July 2020. The German market is also down 5.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Healthcare industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €15.91 per share.業績と収益の成長予測DB:V3V - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202892246112/31/202788125112/31/20268504713/31/202688-5-14N/A12/31/202588-5-14N/A9/30/202588-1004N/A6/30/202588-915N/A3/31/202586-1146N/A12/31/202482-1159N/A9/30/2024814912N/A6/30/2024791711N/A3/31/2024780711N/A12/31/202377-259N/A9/30/202375-25-50N/A6/30/202373-24-61N/A3/31/202371-27-10-3N/A12/31/202269-27-11-4N/A9/30/202263-12-60N/A6/30/202250-11-5-1N/A3/31/202239-6-12N/A12/31/202128-403N/A9/30/202121023N/A6/30/202121033N/A3/31/202120134N/A12/31/202020134N/A9/30/202020145N/A6/30/202020156N/A3/31/202020156N/A12/31/2019201N/A6N/A9/30/2019201N/A6N/A6/30/2019201N/A5N/A3/31/2019201N/A5N/A12/31/2018201N/A5N/A9/30/2018212N/A4N/A6/30/2018211N/A3N/A3/31/2018200N/A2N/A12/31/2017190N/A2N/A9/30/201718-1N/A2N/A6/30/201716-1N/A2N/A3/31/2017171N/A2N/A12/31/2016160N/A2N/A9/30/2016162N/A1N/A6/30/2016162N/A1N/A3/31/2016152N/A1N/A12/31/2015142N/A3N/A9/30/2015141N/A2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: V3Vは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 1.9% ) よりも高い成長率であると考えられます。収益対市場: V3V今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: V3V今後 3 年以内に収益を上げることが予想されます。収益対市場: V3Vの収益 ( 3.1% ) German市場 ( 6.7% ) よりも低い成長が予測されています。高い収益成長: V3Vの収益 ( 3.1% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: V3Vの 自己資本利益率 は、3年後には低くなると予測されています ( 17.1 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/07 05:00終値2026/07/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋FamiCord AG 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Emily HainesFirst Berlin Equity Research GmbHTim KruseMontega AGUlrich HuwaldWarburg Research GmbH
お知らせ • May 30FamiCord AG Confirms Earnings Guidance for 2026FamiCord AG confirmed earnings guidance for 2026. The Management Board confirms its guidance for the 2026 financial year, expecting revenues in a range of EUR 80 million to EUR 90 million.
Price Target Changed • May 21Price target decreased by 13% to €6.50Down from €7.50, the current price target is provided by 1 analyst. New target price is 71% above last closing price of €3.81. Stock is up 0.3% over the past year. The company is forecast to post earnings per share of €0.03 next year compared to a net loss per share of €0.26 last year.
お知らせ • Nov 22FamiCord AG Confirms Earnings Guidance for the Financial Year 2025FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million.
Price Target Changed • Jun 04Price target increased by 15% to €6.00Up from €5.21, the current price target is provided by 1 analyst. New target price is 27% above last closing price of €4.74. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year.
Breakeven Date Change • May 02No longer forecast to breakevenThe analyst covering VITA 34 no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.05m in 2024. New forecast suggests the company will make a loss of €1.50m in 2025.
Price Target Changed • Nov 16Price target decreased to €10.50Down from €12.50, the current price target is an average from 2 analysts. New target price is 19% above last closing price of €8.86. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.59 next year compared to a net loss per share of €0.63 last year.
Reported Earnings • Jun 01First quarter 2026 earnings released: €0.01 loss per share (vs €0.04 loss in 1Q 2025)First quarter 2026 results: €0.01 loss per share (improved from €0.04 loss in 1Q 2025). Revenue: €21.5m (down 2.7% from 1Q 2025). Net loss: €208.0k (loss narrowed 69% from 1Q 2025). Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • May 30FamiCord AG Confirms Earnings Guidance for 2026FamiCord AG confirmed earnings guidance for 2026. The Management Board confirms its guidance for the 2026 financial year, expecting revenues in a range of EUR 80 million to EUR 90 million.
Price Target Changed • May 21Price target decreased by 13% to €6.50Down from €7.50, the current price target is provided by 1 analyst. New target price is 71% above last closing price of €3.81. Stock is up 0.3% over the past year. The company is forecast to post earnings per share of €0.03 next year compared to a net loss per share of €0.26 last year.
お知らせ • May 14FamiCord AG, Annual General Meeting, Jun 24, 2026FamiCord AG, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.
お知らせ • Dec 24+ 3 more updatesFamiCord AG to Report Q3, 2026 Results on Nov 23, 2026FamiCord AG announced that they will report Q3, 2026 results on Nov 23, 2026
お知らせ • Nov 22FamiCord AG Confirms Earnings Guidance for the Financial Year 2025FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million.
お知らせ • May 16FamiCord AG, Annual General Meeting, Jun 25, 2025FamiCord AG, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jan 09+ 3 more updatesVITA 34 AG to Report Q1, 2025 Results on May 28, 2025VITA 34 AG announced that they will report Q1, 2025 results on May 28, 2025
Reported Earnings • Aug 31Second quarter 2024 earnings released: €0.10 loss per share (vs €0.07 loss in 2Q 2023)Second quarter 2024 results: €0.10 loss per share (further deteriorated from €0.07 loss in 2Q 2023). Revenue: €19.5m (up 6.0% from 2Q 2023). Net loss: €1.41m (loss widened 19% from 2Q 2023). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Jun 05First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023)First quarter 2024 results: €0.05 loss per share (improved from €0.18 loss in 1Q 2023). Revenue: €18.6m (up 3.6% from 1Q 2023). Net loss: €785.0k (loss narrowed 73% from 1Q 2023). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings.
New Risk • Jun 05New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€129k net loss in 2 years). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$93.3m).
Price Target Changed • Jun 04Price target increased by 15% to €6.00Up from €5.21, the current price target is provided by 1 analyst. New target price is 27% above last closing price of €4.74. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year.
Breakeven Date Change • May 02No longer forecast to breakevenThe analyst covering VITA 34 no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.05m in 2024. New forecast suggests the company will make a loss of €1.50m in 2025.
お知らせ • Apr 27+ 3 more updatesVITA 34 AG to Report Q1, 2024 Results on May 31, 2024VITA 34 AG announced that they will report Q1, 2024 results on May 31, 2024
New Risk • Apr 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€82.6m market cap, or US$89.5m).
New Risk • Apr 04New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €25m Forecast net loss in 2 years: €1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding).
New Risk • Feb 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€86.3m market cap, or US$93.1m).
Reported Earnings • Nov 26Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022)Third quarter 2023 results: €0.10 loss per share (further deteriorated from €0.02 loss in 3Q 2022). Revenue: €20.4m (up 9.4% from 3Q 2022). Net loss: €1.62m (loss widened €1.41m from 3Q 2022). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.
Reported Earnings • Sep 01Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022)Second quarter 2023 results: €0.07 loss per share (improved from €0.30 loss in 2Q 2022). Revenue: €18.4m (up 10% from 2Q 2022). Net loss: €1.19m (loss narrowed 74% from 2Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
New Risk • Jun 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (€87.1m market cap, or US$95.0m).
New Risk • Jun 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.6m (US$89.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Jun 02First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022)First quarter 2023 results: €0.18 loss per share (in line with 1Q 2022). Revenue: €17.9m (up 16% from 1Q 2022). Net loss: €2.89m (loss widened 2.8% from 1Q 2022). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
お知らせ • May 12Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug CandidateVita 34 AG has started enrollment in Phase I of the Tarcidomgen Kimleucel clinical trial. The drug candidate is an anti-CD19 CAR-T, a chimeric antigen receptor, and the first candidate in Vita 34's Cell & Gene Therapy (CGT) portfolio. After recent clearance by the responsible authorities and the responsible ethics committee, the start of the clinical trial under the name CARLA and the recruitment of the first patient ("First Patient In") is imminent. A total of up to ten patients are expected to be recruited for Phase I of the study, which is the usual number for this type of drug. The recruitment will take place via two clinical centers in Poland. The Management Board of Vita 34 AG expects Phase I to be completed by the end of 2023. The costs related with this phase of the trial have already taken into consideration in the guidance published for 2023. The principal investigator of the CARLA study is Prof. Grzegorz Basak, Professor and Chairman of the Department of Hematology, Transplantation and Internal Medicine at the University Hospital of Warsaw Medical University. Tarcidomgen Kimlucel is being developed through FamiCordTx, a subsidiary of Vita 34 AG that aims to develop proprietary CAR-T drug therapies. FamiCordTx has secured an exclusive license from a U.S. supplier for this purpose in the past and has optimized the technology according to European GMP standards. CAR-T therapy uses a patient's own T cells, which are genetically engineered in a laboratory to produce a protein called a chimeric antigen receptor (CAR). When the modified T-cells are returned to the patient, the CAR enables the T- cells to seek out and destroy cancer cells wherever they are in the body. According to a report by Allied Market Research, the global CAR-T cell therapy market was valued USD 1,7 billion in 2021 and is expected to reach USD 6.1 billion by 2031.
Reported Earnings • May 01Full year 2022 earnings released: €1.71 loss per share (vs €0.63 loss in FY 2021)Full year 2022 results: €1.71 loss per share (further deteriorated from €0.63 loss in FY 2021). Revenue: €68.9m (up 143% from FY 2021). Net loss: €27.1m (loss widened €23.4m from FY 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance.
お知らせ • Dec 03+ 3 more updatesVITA 34 AG to Report Q3, 2023 Results on Nov 21, 2023VITA 34 AG announced that they will report Q3, 2023 results on Nov 21, 2023
Reported Earnings • Nov 24Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021)Third quarter 2022 results: €0.02 loss per share (down from €0.11 profit in 3Q 2021). Revenue: €18.7m (up 230% from 3Q 2021). Net loss: €209.0k (down 147% from profit in 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance.
Price Target Changed • Nov 16Price target decreased to €10.50Down from €12.50, the current price target is an average from 2 analysts. New target price is 19% above last closing price of €8.86. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.59 next year compared to a net loss per share of €0.63 last year.
Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021)Second quarter 2022 results: EPS: €0.30. Revenue: €16.6m (up 206% from 2Q 2021). Net loss: €4.61m (loss widened €4.60m from 2Q 2021). Over the next year, revenue is forecast to grow 48%, compared to a 3.7% growth forecast for the Healthcare industry in Germany.
Reported Earnings • Jun 02First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: €0.18 loss per share (down from €0.01 loss in 1Q 2021). Revenue: €15.5m (up 188% from 1Q 2021). Net loss: €2.81m (loss widened €2.77m from 1Q 2021). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 103%, compared to a 4.8% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 02Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: €0.63 loss per share (down from €0.37 profit in FY 2020). Revenue: €28.4m (up 42% from FY 2020). Net loss: €3.67m (down 343% from profit in FY 2020). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 17% compared to a 5.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Price Target Changed • Apr 27Price target increased to €25.00Up from €19.10, the current price target is provided by 1 analyst. New target price is 108% above last closing price of €12.00. Stock is down 28% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.
Price Target Changed • Dec 18Price target increased to €21.10Up from €19.10, the current price target is an average from 2 analysts. New target price is 40% above last closing price of €15.10. Stock is up 23% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: €5.82m (up 7.4% from 3Q 2020). Net income: €575.0k (down 23% from 3Q 2020). Profit margin: 9.9% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • Sep 01Second quarter 2021 earnings releasedThe company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €5.44m (up 11% from 2Q 2020). Net loss: €12.0k (down 102% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has remained flat.
Reported Earnings • Jun 01First quarter 2021 earnings releasedThe company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €5.38m (up 15% from 1Q 2020). Net loss: €38.0k (down 110% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 02Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019)The company reported a solid full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: €20.1m (flat on FY 2019). Net income: €1.51m (up 104% from FY 2019). Profit margin: 7.5% (up from 3.7% in FY 2019). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Feb 12New 90-day high: €14.05The company is up 12% from its price of €12.55 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.90 per share.
Is New 90 Day High Low • Jan 23New 90-day high: €13.00The company is up 5.0% from its price of €12.35 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Healthcare industry, which is also up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.80 per share.
Price Target Changed • Nov 25Price target raised to €17.50Up from €15.00, the current price target is an average from 2 analysts. The new target price is 41% above the current share price of €12.45. As of last close, the stock is down 8.8% over the past year.
Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS €0.18The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €5.42m (up 1.4% from 3Q 2019). Net income: €745.0k (up 357% from 3Q 2019). Profit margin: 14% (up from 3.0% in 3Q 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Analyst Estimate Surprise Post Earnings • Nov 14Revenue and earnings miss expectationsRevenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 2.9%. Over the next year, revenue is forecast to grow 7.4%, compared to a 4.3% growth forecast for the Healthcare industry in Germany.
Is New 90 Day High Low • Oct 29New 90-day low: €11.15The company is down 5.0% from its price of €11.70 on 30 July 2020. The German market is also down 5.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Healthcare industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €15.91 per share.